These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28124274)

  • 1. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients.
    Yi JW; Kim SJ; Kim JK; Seong CY; Yu HW; Chai YJ; Choi JY; Lee KE
    Ann Surg Oncol; 2017 Nov; 24(12):3754-3762. PubMed ID: 28124274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.
    Ahn HY; Song RY; Ahn HS; Kim HS
    Cancer Res Treat; 2021 Oct; 53(4):1204-1212. PubMed ID: 33592140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
    Tang J; Gui C; Qiu S; Wang M
    World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancer.
    Dong W; Li J; Zhang H; Huang Y; He L; Wang Z; Shan Z; Teng W
    Int J Clin Exp Pathol; 2015; 8(6):7149-56. PubMed ID: 26261608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma.
    Huang Y; Dong W; Li J; Zhang H; Shan Z; Teng W
    BMC Cancer; 2014 May; 14():383. PubMed ID: 24884830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of estrogen receptor-α in human papillary thyroid carcinomas studied by laser- capture microdissection and molecular biology.
    Di Vito M; De Santis E; Perrone GA; Mari E; Giordano MC; De Antoni E; Coppola L; Fadda G; Tafani M; Carpi A; Russo MA
    Cancer Sci; 2011 Oct; 102(10):1921-7. PubMed ID: 21707866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
    Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased Expression of Estrogen Receptors Is Associated with Tumorigenesis in Papillary Thyroid Carcinoma.
    Chou CK; Chi SY; Hung YY; Yang YC; Fu HC; Wang JH; Chen CC; Kang HY
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
    Jia M; Guo Y; Lu X
    Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Xin S; Zhang J
    BMC Cancer; 2020 Nov; 20(1):1143. PubMed ID: 33238942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients.
    Kazaure HS; Roman SA; Sosa JA
    Ann Surg Oncol; 2012 Jun; 19(6):1874-80. PubMed ID: 22065195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
    Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
    Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
    Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
    World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter.
    Hou X; Jiang L; Chen C; Zhu X; Ge M
    Clin Lab; 2015; 61(7):793-9. PubMed ID: 26299079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.